多西他赛联合卡培他滨治疗复发转移乳腺癌的疗效及相关因素研究

目的　探讨低剂量多西他赛联合卡培他滨治疗复发转移乳腺癌的疗效及其预测因素。方法　２００６年６月至２００９年１２月收治３８例复发转移乳腺癌女性患者给予多西他赛联合卡培他滨治疗，具体方案为：多西他赛６０ｍｇ／ｍ２静滴，ｄ１；卡培他滨９５０ｍｇ／ｍ２口服，每日２次，ｄ１～ｄ１４；２１天为１周期。２个周期评价疗效，并随访无进展生存时间（ＰＦＳ）。选取ＰＳ评分、绝经状态、ＥＲ、ＨＥＲ ２、转移数目、既往化疗共６个指标分别建立两分类Ｌｏｇｉｓｔｉｃ回归模型和Ｃｏｘ风险比例模型，分析上述指标对疗效的预测情况。结果　３８例患者均接受２～６个周期化疗，获ＣＲ３例，ＰＲ１８例，ＳＤ１０例，ＰＤ７例，有效率（ＲＲ）为５５.３％（２１／３８）；中位ＰＦＳ为７.１个月（９５％ＣＩ：４.８～９.６个月）。主要毒副反应为恶心呕吐、乏力、白细胞减少和手足综合征等，其中３～４级白细胞减少为１５.８％。６个指标中ＰＳ评分（Ｐ＝０.００３）、绝经状态（Ｐ＝０.０４３）和转移数目（Ｐ＝０.０２１）均与ＲＲ有关，仅ＰＳ评分为ＲＲ的独立预测因素（Ｐ＜０.０５）；Ｃｏｘ风险比例模型显示，ＰＳ评分是ＰＦＳ的独立预测因素（Ｐ＜０.０５）。结论　低剂量多西他赛联合卡培他滨治疗复发转移乳腺癌的疗效好，安全性高；ＰＳ评分可以作为该方案疗效预测的独立因素。

Clinical study of low-dose docetaxel combined with capecitabine for metastatic breast cancer

Objective To evaluate the efficacy and its prognostic factors of low-dose docetaxel and capecitabine combination regimen(XT regimen) for patients with metastatic breast cancer.Methods Thirty-eight patients with metastatic breast cancer from June 2006 to December 2009 received XT regimen(docetaxel 60mg/m2 iv,d1;capecitabine 950mg/m2 oral administrations twice a day,d1-d14;every 21 days was a cycle).The response rate(RR) was evaluated after 2 cycles and progress-free survival(PFS) was recorded.Performance sta...